Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Cardio-Oncology
Published in: Cardio-Oncology 1/2024

Open Access 01-12-2024 | Stem Cell Transplantation | Research

Left and right ventricular global longitudinal strain assessment together with biomarker evaluation may have a predictive and prognostic role in patients qualified for hematopoietic stem cell transplantation due to hematopoietic and lymphoid malignancies – a pilot study description

Authors: Bartosz Puła, Jarosław Kępski, Irena Misiewicz-Krzemińska, Sebastian Szmit

Published in: Cardio-Oncology | Issue 1/2024

Login to get access

Abstract

The hematopoietic stem cell transplantation (HSCT) procedure is considered a cardiovascular burden. This is due to the potentially cardiotoxic cytostatic agents used before and the risks associated with peri-transplant procedures. We designed a pilot study to determine the clinical utility of the new ST2 marker; furthermore, we routinely assessed cardiac parameters in HSCT recipients. Based on previous cardio-oncology experience in lung and prostate cancer, we can confirm the prognostic and predictive value of classic cardiac biomarkers and modern echocardiography parameters such as global longitudinal strain of the left and right ventricle. After conducting this pilot study we can create a predictive and prognostic model for patients undergoing HSCT. This will greatly enrich our clinical practice, especially in treating older people.
Literature
1.
Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229–361
2.
Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen‐Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society. Eur J Heart Fail. 2020;22:1945–60.CrossRefPubMed
3.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.CrossRefPubMed
4.
López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41:1720–9.CrossRefPubMed
5.
Caro-Codón J, López-Fernández T, Álvarez-Ortega C, Zamora Auñón P, Rodríguez IR, Gómez Prieto P, et al. Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol. 2022;29:859–68.CrossRefPubMed
6.
Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2021;ehab674.
7.
Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler‐Klein J, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22:1504–24.CrossRefPubMed
8.
Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1966–83.CrossRefPubMed
9.
Riccardi M, Myhre PL, Zelniker TA, Metra M, Januzzi JL, Inciardi RM. Soluble ST2 in Heart failure: a clinical role beyond B-Type natriuretic peptide. JCDD. 2023;10:468.CrossRefPubMedPubMedCentral
10.
Hjort M, Eggers KM, Lindhagen L, Baron T, Erlinge D, Jernberg T, et al. Differences in biomarker concentrations and predictions of long-term outcome in patients with ST-elevation and non-ST-elevation myocardial infarction. Clin Biochem. 2021;98:17–23.CrossRefPubMed
11.
Ren Y, Hou M, Ren Y, Zhang L. Diagnostic efficacy of serum ST2 in patients with ASC. Clin Lab Anal. 2022;36:e24511.CrossRef
12.
Gjærde LK, Ostrowski SR, Schierbeck F, Andersen NS, Friis LS, Kornblit B, et al. Pretransplantation plasma ST2 level as a prognostic biomarker of 1-Year nonrelapse mortality in allogeneic hematopoietic cell transplantation. Transplantation Cell Therapy. 2023;29:97e1–6.CrossRef
13.
Krawiec KM, Czemerska M, Stelmach P, Wierzbowska A, Pluta A. Assessment of colonization and infection epidemiology in patients undergoing autologous hematopoietic stem cell transplantation: a single-center study. Acta Haematol Pol. 2022;53:133–40.CrossRef
14.
Limbach M, Kuehl R, Dreger P, Luft T, Rosenberger F, Kleindienst N, et al. Influencing factors of cardiorespiratory fitness in allogeneic stem cell transplant candidates prior to transplantation. Support Care Cancer. 2021;29:359–67.CrossRefPubMed
15.
Czarnogórski MC, Maziewski M, Ruckemann-Dziurdzińska K, Sakowska J, Zieliński M, Witkowski JM et al. Long-term allogeneic hematopoietic cells transplantation survivors proinflammatory cytokine profile compared to their respective donors and immunophenotype differences depending on GvHD history and infection status. Acta Haematol Pol. 2023;VM/OJS/J/92633.
16.
Joks M, Rupa-Matysek J, Matuszak M, Łojko-Dankowska A, Gil L. Neutropenic enterocolitis and multidrug-resistant bacteria colonization in lymphoma patients undergoing autologous stem cell transplantation. Acta Haematol Pol. 2022;53:258–66.CrossRef
17.
Kępski J, Szmit S, Lech-Marańda E. Characteristics of patients with newly diagnosed hematological malignancies referred for echocardiography. Front Oncol. 2024;14:1283831.CrossRefPubMedPubMedCentral
18.
Zaborowska-Szmit M, Kowalski DM, Piórek A, Krzakowski M, Szmit S. A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors. Pharmacol Rep. 2016;68:1140–8.CrossRefPubMed
19.
Wilk M, Waśko-Grabowska A, Skoneczna I, Szczylik C, Szmit S. Cardiac biomarkers and geriatric assessment in metastatic castrate-resistant prostate cancer during abiraterone acetate therapy – a cardio-oncology study. Cancer Control. 2022;29:107327482211406.CrossRef
20.
Mędrek S, Szmit S. Baseline Electrocardiographic and echocardiographic assessment may help predict survival in lung cancer patients—a prospective cardio-oncology study. Cancers. 2022;14:2010.CrossRefPubMedPubMedCentral
21.
Mędrek S, Szmit S. Echocardiography-assessed changes of left and right ventricular cardiac function may correlate with progression of advanced lung cancer—a generating hypothesis study. Cancers. 2022;14:4770.CrossRefPubMedPubMedCentral
Metadata
Title
Left and right ventricular global longitudinal strain assessment together with biomarker evaluation may have a predictive and prognostic role in patients qualified for hematopoietic stem cell transplantation due to hematopoietic and lymphoid malignancies – a pilot study description
Authors
Bartosz Puła
Jarosław Kępski
Irena Misiewicz-Krzemińska
Sebastian Szmit
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cardio-Oncology / Issue 1/2024
Electronic ISSN: 2057-3804
DOI
https://doi.org/10.1186/s40959-024-00210-8

Other articles of this Issue 1/2024

Cardio-Oncology 1/2024 Go to the issue

Case Report

Secondary cardiac lymphoma presenting with cardiac tamponade and cardiac mass: a case report

Research

Right ventricle involvement in patients with breast cancer treated with chemotherapy

Research

Two-dimensional speckle tracking echocardiography in chemotherapy-induced cardiotoxicity in females with breast cancer

Research

Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: results from a pilot proof-of-concept study

Research

Formative research to adapt a cardiac rehabilitation program to breast cancer survivors: the heart health after cancer treatment (HEART-ACT) study

Correspondence

How do breast cancer clinical trials approach cardiovascular safety: targeted or generalized?